Antidepressant and antipsychotic use in an Italian pediatric population by Clavenna, Antonio et al.
RESEARCH ARTICLE Open Access
Antidepressant and antipsychotic use in an
Italian pediatric population
Antonio Clavenna
1*, Margherita Andretta
2, Paola Pilati
2, Maurizio Dusi
3, Michele Gangemi
4, Maria Beatrice Gattoni
4,
Giuseppe Lombardo
4, Leonardo Zoccante
5, Luigi Mezzalira
2 and Maurizio Bonati
1
Abstract
Background: The safety and effectiveness of psychotropic drug use in the paediatric population is widely debated,
in particular because of the lack of data concerning long term effects.
In Italy the prevalence of psychotropic drug prescriptions increased in the early 2000s and decreased afterwards. In
such a context, a study with the aim to estimate the incidence and prevalence of psychotropic drug prescription
in the paediatric population and to describe diagnostic and therapeutic approaches was performed.
Methods: The study population was composed of 76,000 youths less than 18 years and living in the area covered
by the local health unit of Verona, Italy. The data source was the Verona local health unit’s administrative
prescription database. Prevalence and incidence of antidepressant and/or antipsychotic drug prescriptions in the
2004-2008 period were estimated. Children and adolescents receiving antidepressant and/or antipsychotic drug
prescriptions between 1 January 2005 and 31 December 2006 were identified and questionnaires were sent to the
prescribers with the aim to collect data concerning diagnostic and therapeutic approaches, and care strategies.
Results: The prevalence of psychotropic drug prescriptions did not change in the 2004-2008 period, while
incidence slightly increased (from 7.0 in 2005 to 8.3 per 10,000 in 2008). Between 1 January 2005 and 31 December
2006, 111 youths received at least one psychotropic drug prescription, 91 of whom received antidepressants. Only
28 patients attended child and adolescent psychiatry services. Information concerning diagnostic and therapeutic
approaches, and care strategies was collected for 52 patients (47%). Anxiety-depressive syndrome and attention
disorders were the diseases for which psychotropic drugs were most commonly prescribed. In all, 75% youths also
received psychological support and 20% were prescribed drugs for 2 or more years.
Conclusions: Despite the low drug prescription prevalence, the finding that most children were not cared for by
child and adolescent psychiatric services is of concern and calls for a systematic, continuous monitoring of
psychopharmacological treatments.
Background
Safety and efficacy of psychotropic drug use in the pae-
diatric population have been widely debated, in particu-
lar due to the lack of data concerning long term effects
[1,2]. Moreover, a link between the use of selective sero-
tonin reuptake inhibitors (SSRIs) and increased risk of
suicide ideation has been documented in the paediatric
population and in young adults[3,4].
Considering antidepressants, the benefit of SSRIs seems
to be greater in general anxiety disorders, intermediate in
obsessive compulsive disorder (OCD), and modest in
major depressive disorder (MDD) [5].
Moreover, the efficacy of pharmacological therapies
for MDD in children and adolescents is controversial
[1]. A systematic review of the literature did not find a
statistically significant difference between tricyclic anti-
depressants and placebo [6]. In addition, taking SSRIs
into account, the risk-benefit profile appears favourable
only for fluoxetine [5,7]. Children with MDD were
found to be more responsive to placebo compared to
children with other neuropsychiatric disorders and this
finding may, at least partly, explain the low efficacy of
antidepressants [8].
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efficacy of antipsychotics mainly involved the second
generation drugs. In particular, a systematic review con-
cerning the treatment of psychosis and bipolar disorder
in children and adolescents found a total of 18 RCTs
that evaluated the efficacy of olanzapine (7 trials), risper-
idone and quetiapine (5), clozapine (4), and aripiprazole
(3) [9].
The only two first generation antipsychotics for which
RCTs are available are haloperidol (mainly for schizo-
phrenia and Tourette’s syndrome) and pimozide (Tour-
ette’s syndrome). The evidence on the efficacy of the
other first generation antipsychotics is scant and limited
to case series or uncontrolled studies [10].
A Cochrane Collaboration systematic review com-
pared risperidone to placebo in children with autism
spectrum disorder, documenting its efficacy in decreas-
ing behavioral symptoms (irritability and aggressive
behavior) [11]. Risperidone was found to be effective
also in reducing symptoms in children and adolescents
with disruptive behavior. Fewer data are available con-
cerning the efficacy of other antipsychotics in pervasive
and disruptive behavior [12].
However, in evaluating the safety and efficacy of psy-
chotropic drugs, the chance that results may be biased
by conflicts of interests should be taken into account
[13].
Few psychotropic drugs are licensed for use in chil-
dren in Italy, and in Europe in general, and for some
diseases only. Sertraline and fluvoxamine are licensed in
Italy and in most of the European countries for the
treatment of OCD (in children ≥ 6 years), fluoxetine is
licensed for MDD in children ≥ 8 years, and imipramine
is licensed in Italy for children ≥ 6 years, but for noctur-
nal enuresis only.
Haloperidol, periciazine, risperidone, chlorpromazine,
and levomepromazine are the antipsychotics licensed for
use in children in Italy. However, the Summary of Pro-
duct Characteristics reports the paediatric dosage sche-
dule only for the first three drugs. Aripiprazole was
licensed in 2009 by the European Medicines Agency for
the treatment of schizophrenia in adolescents over
15 years old. In the United States, but not in Europe,
the second generation antipsychotics olanzapine and
quetiapine are also licensed for use in children.
The prevalence of psychotropic drug prescriptions in
the paediatric population differs among countries, with
the highest values in the United States [14-17]. In a
three-country comparison study, the psychotropic medi-
cation prevalence in 2000 was 6.7% in the United States,
2.9% in the Netherlands, and 2.0% in Germany [15]. A
psychotropic drug prescription prevalence of 2.2% was
estimated in France in 2004 [16], and one of 4.9% in
Iceland in 2007 [17].
In Italy, the drug prescription prevalence increased in
the 2000-2002 period, in particular the prevalence of
SSRIs, and decreased afterwards, reaching a value of
around 2 per 1,000 youths under 18 years in 2004, with
differences between geographical settings [18]. In fact, in
a sample of 27 Italian local health units the prevalence
ranged from 0.8‰ to 6‰ [18].
Drug utilization studies performed in Italy analysed
data collected in prescription databases, with some lim-
itations, mainly: the lack of information concerning the
diseases for which drugs were prescribed, the use of non
reimbursed drugs, and the access to non pharmacologi-
cal therapies.
In this context, a retrospective study was performed in
a sample of children and adolescents treated with
psychotropic drugs, in an homogeneous geographical
context (the local health unit, LHU, of Verona, in north-
ern Italy), with the aim to evaluate the diagnostic and
therapeutic approaches in the management of psychia-
tric disorders.
Methods
Psychotropic drug prescriptions dispensed in the 2004-
2008 period to children and adolescents < 18 years old
living in the area covered by the Verona local health
unit (LHU) were analysed. The data source was the Ver-
ona LHU’s administrative prescription database that
stores all community (i.e. outside hospital) prescriptions
reimbursed by the National Health Service (NHS). The
structure of the database has been described in detail
elsewhere [19]
Psychotropic drugs were classified according to the
World Health Organization categories and comprised
the following subgroups of the Anatomic Therapeutic
Chemical (ATC) classification system: antidepressants
(N06A) and antipsychotics (N05A). Anticonvulsants
were excluded since in children they are mainly used to
treat epilepsy, while anxiolytics were excluded because
they are not reimbursed by the Italian National Health
Service and were thus not present in the prescription
database. Stimulants were not taken into account since
methylphenidate and atomoxetine were marketed in
Italy only in 2007.
The prescription trend in the 2004-2008 period was
analyzed, and the annual prevalence and incidence
were calculated. Prevalence was defined as the number
of individuals who received at least one psychotropic
drug prescription per 10,000 individuals in the popula-
tion, and incidence was defined as the number of peo-
ple who received a psychotropic drug prescription for
the first time per 10,000 youths in the population.
Incident users were defined as youths who did not
receive any psychotropic drug prescription in the pre-
ceding consecutive 12 months.
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cents who received a psychotropic drug in the 2005-
2006 period were identified and, in November 2007, a
previously validated questionnaire was sent to the pri-
mary care physician (family paediatrician or general
practitioner) who cared for the youth.
Youths were selected using the national identification
number (the so called fiscal code, an alphanumeric uni-
vocal code). The selection of the sample was performed
by a pharmacist in Verona LHU, who usually accessed
the prescription database for administrative reasons.
Each physician received a list reporting the fiscal code
numbers of the children and adolescent in his/her
charge, with the aim to allow him/her to identify the
patient and fill in the questionnaire. Only the physician
who cared for the child was able to identify the patient.
Data concerning diagnostic approaches, pharmacological
and non pharmacological therapies, neuropsychiatric
disorders for which drugs were prescribed, hospitaliza-
tions, and side effects were collected. Moreover, the out-
come was evaluated using the clinical global impression
improvement (CGI-I) scale. A similar questionnaire,
regarding the same previously identified youths, was
also sent to child psychiatrists working in Verona outpa-
tient and hospital child and adolescent neuropsychiatry
services.
In Italy, children are assigned to a family paediatrician
until they are 6 years old; afterwards, the parents can
choose to remain with that paediatrician until child is
14 years old or to register the child with a general prac-
titioner. All adolescents over 14 years of age are
assigned to a general practitioner.
Child and adolescent neuropsychiatry services exist at
the hospital and community level to care for children
and adolescents with neurologic and/or psychiatric dis-
orders and for their families [20].
The study was approved by the Verona LHU’sE t h i c s
Review Board. Data were analysed using an anonymous
patient code, study specific and different from the fiscal
code.
A c
2 test was performed in order to compare the pro-
file of children receiving recurrent (>1 prescriptions)
with children receiving occasional prescriptions.
Significance of the prevalence linear trend (c
2 trend)
was assessed across years.
A P value < 0.05 was considered statistically significant.
Results
Prevalence and incidence of psychotropic drug
prescriptions
The prevalence of psychotropic drug prescriptions did not
change in the 2004-2008 period (c
2 t = 0.08; p = 0.78).
The incidence slightly increased, from 7.0 per 10,000 in
2005 to 8.3 per 10,000 in 2008, but the increase was not
statistically significant (c
2 t = 1.32; p = 0.25).
While the prevalence of antidepressants was quite
stable, the prevalence of antipsychotics decreased in the
2004-2006 period and then increased to a value similar
to that of 2004. (Figure 1)
Citalopram (1.3 per 10,000 youths), sertraline (1.2 per
10,000 youths), and paroxetine (1.1 per 10,000) were the
most prescribed psychotropic drugs in 2004, while par-
oxetine (1.5 per 10,000), sertraline (1.5 per 10,000), and
escitalopram (1.0 per 10,000) were the drugs most com-
monly prescribed in 2008.
In the 2005-2006 period 111 children and adoles-
cents (54 boys and 57 girls) 2-17 years old received at
least one psychotropic drug prescription: 86 of them
received antidepressants, 20 antipsychotics, and 5 both.
A total of 14 youths received prescriptions in either
2005 or 2006.
Figure 2 reports the distribution of drug prescription
prevalence by gender and age. Prevalence increased with
increasing age, with the highest value in adolescent girls
(28 per 10,000 person-years; 95%CI 27-29 per 10,000
person-year).
A total of 25 different drugs were prescribed. Those
most commonly prescribed were sertraline and amitryp-
tiline (14% of the youths), paroxetine (12%), and citalo-
pram (10%). Haloperidol was the most commonly
prescribed antipsychotic (8%).
Every child received a mean of 2.4 prescriptions (med-
ian: 1; interquartile range, IQR: 1-3) and 3.7 packages
(median: 2; IQR: 1-5).
In all, 56 youths received only 1 prescription (occa-
sional prescription) and 39 youths received one medica-
tion package only during the 2-year observation period.
No differences were found between youths receiving sin-
gle versus recurrent prescriptions for age, gender, or
drug class.
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Figure 1 Trend of psychotropic drug prescription prevalence in
the 2004-2008 period in the Verona local health unit.
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not licensed for use in children.
Ninety physicians cared for 111 youths. More specifi-
cally, 69 general practitioners cared for 89 patients,
while 21 family paediatricians cared for 22 children.
General practitioners and paediatricians prescribed psy-
chotropic drugs to 90 patients (81%), while for 21
youths (19%) drugs were prescribed by a child psychia-
trist or psychiatrist. In all, 28 children attended a child
psychiatry service; the percentage of children attending
such a service was higher among youths with recurrent
prescriptions (33% versus 18%).
Results of the survey
Profile of responders
Data from questionnaires were available for 52 patients,
31 of which received recurrent prescriptions.
Youths for whom questionnaires were available were
younger than youths for whom information was not
provided: the age expressed as mean ± standard devia-
tion was 13.5 ± 3.1 years versus 15.2 ± 3.3 years, respec-
tively (p = 0.02). In particular, it was possible to collect
data only for 37% of the adolescents compared with 73%
of the younger children (c
2 = 10.3, p = 0.0006). No sta-
tistically significant differences were found between
gender.
Children included in the survey received a greater
number of prescriptions during the 2 year observation
period: the mean number of prescriptions (± standard
deviation) was 3.6 ± 5.7 versus 1.9 ± 1.4 in children for
whom data were not provided (p = 0.002).
The percentage of children with recurrent prescrip-
tions included in the survey was slightly higher than
that of children with one prescription only (56 ver-
sus 38%, p = 0.05). For 26 patients the questionnaire
was filled in by the primary care physician and for
26 by the child psychiatrist (for 20 by both types of
physicians).
Therapy
A total of 38 patients received antidepressants (43% of
antidepressant users) and 17 antipsychotics (65%), while
3 received both.
23 children and adolescents received psychotropic
drug prescriptions also during 2007: 14 were treated
with antidepressants, and 11 with antipsychotics, 2 with
both. In all, 39 patients (75%) received a psychological
therapy in the 2005-2006 period, 18 of whom received it
also during 2007.
Seven youths reported side effects to their physician (5
in therapy with antipsychotics and 2 with antidepres-
sants), in particular: increased appetite (3), drowsiness,
dyskinesia, irritability, and seizures (1 each). Only
1 patient stopped treatment because of side effects.
Diagnostic and care pathways
Anxiety-depressive disorders (33% of the cases) and
attention deficit hyperactivity disorder (ADHD) (21%)
were the disorders for which drugs were more com-
m o n l yp r e s c r i b e d .T h ep r e v a l e n c eo fa n x i e t y - d e p r e s s i v e
disorders treated with drugs in Verona’sL H Uw a se s t i -
mated at 2.4 cases per 10,000 (95%CI 2.3-2.5 per
10,000) and the prevalence of ADHD at 1.4 per 10,000
(95%CI 1.3-1.5 per 10,000).
The diagnosis was made for the first time by a child
psychiatrist in 73% of the cases. Sixteen patients were
visited by at least one other specialist before the diagno-
sis was made and 18 were visited by other specialists
after the diagnosis was made. In all, 10 youths were vis-
ited by 3 or more specialists.
During 2007, 21% of the patients were followed by
paediatricians or general practitioners only.
Outcome
According to the physician’s judgment, the symptoms of
73% of the youths resolved partially or completely.
For 24 out of 52 patients (46%) the disorder was rated
by the physician as improved/very improved (CGI-I 1 or
2), for 19 there was no change or minimal improvement,
while only in 3 cases the disease worsened.
In all, 18 youths considered as improved/very
improved were taking antidepressants (out of 38 treated
with these medications; 47.4%) and 6 were taking anti-
psychotics (out of 17; 35.3%). Thirteen of 24 children
(54%) received recurrent prescriptions in the 2005-2006
period.
Two patients treated with antidepressants (citalopram,
fluvoxamine) and 2 treated with antipsychotics (olanza-
pine, clotiapine) attempted suicide. All 4 patients were
adolescents: 3 male and 1 female.
Thirty-one patients (60%) experienced some difficul-
ties in their school performances: 9 had ADHD and 9
anxiety-depressive disorder.
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Figure 2 Prevalence of psychotropic drug prescriptions (per
10,000 person-years) by gender and age.
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Page 4 of 7Psychiatric disorders in the family members
In 15 cases, at least one parent had a psychiatric disor-
der and in 12 cases at least one family member took
psychotropic drugs (antidepressants and/or benzodiaze-
pines). The chance to have a family member with a psy-
chiatric disorder was greater in youths with recurrent
prescriptions compared with youths with occasional pre-
scriptions (42 versus 10%; chi square 4.9; p = 0.03).
Discussion
In Verona LHU’s large population, the prevalence of
psychotropic drug prescriptions was lower than in Italy
as a whole [18,21] and in other countries [14-17].
Drug utilization studies found a greater prescription
prevalence of antidepressants in the United States (10%),
followed by Iceland (2.3%), while in other European
countries the antidepressant prescription prevalence
ranged from 0.2 to 0.6%[14-17,22,23]. A similar pattern
was observed for antipsychotics, with a prevalence ran-
ging from 0.7 per 1,000 in Italy to more than 1% in the
United States and Iceland [14-17,24].
T h ep r e v a l e n c eb yg e n d e ra n da g ei sc o n s i s t e n tw i t h
the findings of other drug utilization studies and with
the epidemiological features of the disorders.
Some data need to be commented on. First of all, the
fact that antidepressants are prescribed occasionally:
37% of youths received one medication package only
during the 2-year observation period, which was not suf-
ficient to cover an 8 week treatment period.
Paroxetine, citalopram, and escitalopram are among
the most prescribed antidepressants, despite the fact
that they are not licensed for use in children. Moreover,
the evidence on efficacy is scant and warnings were
issued by Italian and international drug regulatory agen-
cies concerning the risk of increased risk of suicide idea-
tion [25,26]. In particular, it is interesting to note that
the prevalence of paroxetine increased slightly over
time, while the prevalence of escitalopram doubled from
2005 to 2008, and this drug became the third most pre-
scribed psychotropic drug in 2008. This finding is con-
sistent with the use of antidepressants in the adult
population, where escitalopram was the most prescribed
drug [27], but only 2 randomised controlled trials evalu-
ated the safety and efficacy of this drug in the paediatric
population, with conflicting results [28,29].
In contrast, fluoxetine, the only SSRI licensed for
MDD and for which evidence of efficacy exists [5-7],
was scantly prescribed.
Unfortunately, although a few reminders were sent to
physicians, there was a low response rate to the ques-
tionnaire; in particular there was a lower compliance by
general practitioners, and concerning adolescents.
However, children included in the survey received a
greater number of prescriptions during the 2 year
observation period and, therefore, it may be hypothe-
s i z e dt h a tm o s to ft h ep a t i e n t sf o rw h i c hd a t aw e r en o t
provided had mild acute disorder (e.g. anxiety) managed
exclusively by the general practitioners, while the survey
was able to capture patients with chronic disorders. The
greater percentage of youths with recurrent prescription
included in the survey (physicians’ responders) may sup-
port this hypothesis. Moreover, it was possible to collect
data for all 14 youths who received drug prescriptions
in either 2005 or 2006.
In all, 47% of the youths resulted still in therapy when
data collection began; considering youths who were
receiving psychotropic drug prescriptions during 2005,
the rate was 20%.
In nearly all cases the drug therapy was integrated
with a psychological treatment, as recommended by
international treatment guidelines [30].
On the contrary, only 28 children and adolescents
(25% of psychotropic users) attended child psychiatric
services. This fact underlines a low adherence to the
standard care approach.
In ¾ of the cases a partial or complete resolution of
symptoms was reported by the physicians, even though
only for 46% of the patients the CGI-I was < 3 (very
much improved or improved). The percentage decreased
to 35% when considering the youths with recurrent
prescriptions.
Almost all patients were visited by a child psychiatrist,
nearly half of them by 2, and 20% by at least three dif-
ferent specialists. The frequent request for a second (or
third) opinion may reflect the disease complexity and
the parents’ difficulties in facing the disorder.
The main strength of this study was the possibility to
collect data concerning the disease for which drugs were
prescribed.
As expected, anxiety-depressive disorders and atten-
tion deficit disorders were the diseases for which drugs
were more commonly prescribed, and covered half of
the children receiving psychotropic drug prescriptions.
The prevalence of pharmacologically treated anxiety-
depressive disorder was roughly estimated at 2.4 per
10,000 and the prevalence of ADHD at 1.4 per 10,000.
For both diseases these estimates are lower than
expected on the basis of the epidemiological data col-
lected at national and international levels [14,31], and
underline the need for prospective studies with the aim
to better define the burden and the prevalence of these
diseases. The prevalence of drug treated patients may be
underestimated, in particular for ADHD since methyl-
phenidate and atomoxetine were not licensed in Italy
before 2007. The estimate in this study is, however, con-
sistent with an analysis of data collected in the national
registry that monitors children treated with methylphe-
nidate or atomoxetine (set up in 2007, when the drugs
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cases per 10,000 in the Lombardy region [32]. However,
the rough estimate of children requiring pharmacologi-
cal treatment for ADHD in Italy is 66 per 10,000 [32],
and it is therefore possible that many children with
ADHD in Verona did not receive the appropriate ther-
apy for the disease.
Despite the small sample and the fact that the study
was not aimed to investigate drug safety, it should be
n o t e dt h a t7o u to f5 2y o u t h se x p e r i e n c e ds i d ee f f e c t s ,
all of which were known and previously reported
[33,34]. The fact that 4 cases of suicide attempt or idea-
tion were reported should also be highlighted, even if it
i sn o tp o s s i b l et od i s c r i m i n a t eb e t w e e nt h er o l eo ft h e
disease and that of the drugs.
One third of the youths had at least one family mem-
ber with a psychiatric disorder and/or in therapy with
psychotropic drugs. This study did not permit an analy-
sis of whether this percentage is higher than in families
without psychiatric disorders. However, some differences
were observed between patients with recurrent versus
occasional prescriptions, indicating that the prevalence
of severe psychiatric disorders may be higher among
youths whose parents have psychiatric disorders [35,36].
Strengths and limitations
This is the first Italian study investigating the diagnostic
and therapeutic approaches in children and adolescents
treated with psychotropic drugs.
There are some limitations, however. First of all, this
study was performed in a local setting (even if quite
large) and it may not described the national situation,
both in terms of prescription prevalence and
approaches. Moreover, the number of youths with a psy-
chotropic drug prescription was small, and only for half
of them it was possible to obtain data concerning the
diagnostic and therapeutic approaches due to the low
physician response rate. It is likely that many data con-
cerning prescriptions made by primary care physicians
without the child psychiatrist’s advice (e.g. SSRIs for
anxiety syndrome in adolescents) were missed. Finally, it
was not possible to collect systematically information
concerning the treatment duration or dosage, the num-
ber of medical visits, or the kind of psychotherapy
performed.
Conclusions
Despite some limitations, this study highlights that there
is a need to define (and to comply with) appropriate
diagnostic and therapeutic approaches for child and
adolescent psychiatric disorders. In most instances, psy-
chotropic drugs were prescribed by general practitioners
without the advice of child psychiatrists, as occasional
treatment of acute disorders, using drugs not licensed
for use in the paediatric population.
Educational interventions with the aim to improve the
rational use of psychotropic drugs in children and ado-
lescents are therefore needed.
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